• 1. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
• 2. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 3. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
• 4. An investigation of surface properties, local elastic modulus and interaction with simulated pulmonary surfactant of surface modified inhalable voriconazole dry powders using atomic force microscopy
  Michael Kappl,Paul M. Young,Daniela Traini,Sanyog Jain RSC Adv., 2016,6, 25789-25798
• 5. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471

• Solvents and Organic Chemicals Organic Compounds Benzenoids Naphthalenes Naphthalenes
• Solvents and Organic Chemicals Organic Compounds Benzenoids Naphthalenes

Introduction to (11bR)-N-Methyl-N-[(R)-1-phenylethyl]-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-amine (CAS No. 1021439-57-5)

(11bR)-N-Methyl-N-[(R)-1-phenylethyl]-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-amine is a complex organic compound that has garnered significant attention in the field of pharmaceutical chemistry due to its unique structural features and potential biological activities. This compound, identified by its CAS number 1021439-57-5, belongs to a class of heterocyclic molecules that exhibit promising properties for further research and development in medicinal applications.

The molecular structure of this compound is characterized by a dinaphtho[2,1-d:1',2'-f] core, which is a fused system of two naphthalene rings connected in a specific manner. This arrangement contributes to the compound's rigidity and stability, making it an attractive candidate for drug design. Additionally, the presence of a dioxaphosphepine ring system introduces a sulfur and phosphorus atom into the molecular framework, which can influence the compound's electronic properties and interactions with biological targets.

One of the most intriguing aspects of (11bR)-N-Methyl-N-[(R)-1-phenylethyl]-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-amine is its stereochemistry. The (11bR) configuration and the (R)-configuration at the chiral centers play a crucial role in determining the compound's biological activity. stereochemistry is essential for ensuring that the molecule interacts correctly with biological targets, such as enzymes and receptors. The precise arrangement of atoms in this compound can lead to selective binding and potent effects.

In recent years, there has been growing interest in developing new therapeutic agents that target specific biological pathways. The unique structural features of (11bR)-N-Methyl-N-[(R)-1-phenylethyl]-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-amine make it a promising candidate for such applications. For instance, studies have suggested that this compound may have inhibitory effects on certain enzymes involved in cancer progression. The dioxaphosphepine moiety has been shown to interact with metal ions and other substrates in ways that could disrupt tumor growth mechanisms.

Furthermore, the presence of aromatic rings in the dinaphtho core suggests potential interactions with DNA and other nucleic acids. This property is particularly relevant in the context of developing agents that can modulate gene expression or interfere with DNA replication in cancer cells. Preliminary research has indicated that derivatives of this compound may exhibit antitumor activity by inhibiting key enzymes involved in cell proliferation.

The synthesis of (11bR)-N-Methyl-N-[(R)-1-phenylethyl]-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-amine is a challenging task due to its complex structure. However, advances in synthetic chemistry have made it possible to construct such molecules with increasing precision. The use of chiral auxiliaries and catalysts has been crucial in achieving the desired stereochemical outcomes. These methods ensure that the final product retains the necessary chiral centers for biological activity.

Once synthesized, the pharmacological evaluation of this compound is critical to understanding its potential therapeutic applications. In vitro assays can provide initial insights into its activity against various biological targets. Additionally, preclinical studies in animal models are essential for assessing its safety and efficacy before human trials can be conducted. These studies will help determine whether this compound can be developed into a viable drug candidate.

The development of new drugs is often a lengthy and complex process. However, compounds like (11bR)-N-Methyl-N-[(R)-1-phenylethyl]-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-amine offer hope for novel therapeutic approaches by leveraging structural complexity to achieve high selectivity and potency. As research continues to uncover new biological targets and mechanisms of disease, compounds with unique structures like this one may play a pivotal role in addressing unmet medical needs.

In conclusion, (11bR)-N-Methyl-N-[(R)-1-phenylethyl]-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-amine (CAS No. 1021439-57-5) is a fascinating molecule with significant potential in pharmaceutical research. Its complex structure and stereochemistry make it an attractive candidate for further development as a therapeutic agent. As more research emerges on its biological activities and synthetic methodologies, this compound may contribute to advancements in drug design and discovery.

• 712352-04-0(N-(Dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-yl)-N-[(alphaS)-alpha-methylbenzyl]methanamine)
• 712352-08-4(N,N-Bis((R)-1-phenylethyl)dinaphtho-2,1-d:1',2'-f1,3,2dioxaphosphepin-4-amine)
• 209482-27-9((S,S,S)-(3,5-Dioxa-4-phosphacyclohepa2,1-a:3,4-a’dinaphthalen-4-yl)bis(1-phenylethyl)amine)
• 415918-91-1((11bR)-N,N-bis[(1R)-1-phenylethyl]-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-amine)
• 380230-02-4(N,N-Bis(1S)-1-phenylethyldinaphtho2,1-d:1',2'-f1,3,2dioxaphosphepin-4-amine)
• 497883-22-4((11bS)-N,N-bis[(1R)-1-phenylethyl]-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-amine)
• 209482-28-0(N,N-Bis(1-phenylethyl)-12,14-dioxa-13-phosphapentacyclo[13.8.0.02,11.03,8.018,23]tricosa-1(15),2(11),3,5,7,9,16,18,20,22-decaen-13-amine)
• 874221-90-6(N-(Dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-yl)-N-[(alphaS)-alpha-methylbenzyl]methanamine)
• 500103-26-4(N N-BIS-[(R)-1-PHENYLETHYL]DIBENZO[D F][)
• 376355-58-7(N,N-Bis((S)-1-phenylethyl)dibenzo[d,f][1,3,2]dioxaphosphepin-6-amine)